Pure Global

A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration - Trial NCT03626636

Access comprehensive clinical trial information for NCT03626636 through Pure Global AI's free database. This Phase 2 trial is sponsored by Allegro Ophthalmics, LLC and is currently Completed. The study focuses on Dry Age-related Macular Degeneration. Target enrollment is 42 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT03626636
Phase 2
Completed
drug
Trial Details
ClinicalTrials.gov • NCT03626636
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration
A Randomized Controlled, Double-Masked, Crossover Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration

Study Focus

Risuteganib

Interventional

drug

Sponsor & Location

Allegro Ophthalmics, LLC

Gilbert,Phoenix,Beverly Hills,Altamonte Springs,Indianapolis,McAllen,San Antonio, United States of America

Timeline & Enrollment

Phase 2

Aug 01, 2017

Apr 04, 2019

42 participants

Primary Outcome

Change in BCVA

Summary

To evaluate the safety and exploratory efficacy of 1.0mg of Luminate® in patients with
 Intermediate Non-Exudative Macular Degeneration

ICD-10 Classifications

Peripheral retinal degeneration
Corneal degeneration
Hereditary retinal dystrophy
Optic atrophy in diseases classified elsewhere
Disorders of choroid and retina

Data Source

ClinicalTrials.gov

NCT03626636

Non-Device Trial